University of Gothenburg
Department of Psychiatry and Neurochemistry
Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, leads the UK DRI Fluid Biomarker Laboratory at UCL and is a Key Member of the Hong Kong Center for Neurodegenerative Diseases. His main research focus and clinical interest are fluid biomarkers for brain diseases, neurodegenerative disease in particular.

Moderator of 2 Sessions

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
08:30 AM - 10:30 AM
Room
ONSITE PLENARY: 115-117

Presenter of 5 Presentations

Biomarkers: The reality check

Session Type
PRE CONFERENCE SYMPOSIUM
Date
Tue, 15.03.2022
Session Time
12:30 PM - 05:30 PM
Room
ONSITE: 112
Lecture Time
01:50 PM - 02:50 PM

Balancing innovation and access: how do we optimize a standard of care and equity in Alzheimer’s?

Session Type
SPONSORED SYMPOSIUM
Date
Fri, 18.03.2022
Session Time
12:15 PM - 01:25 PM
Room
ONSITE: 114
Lecture Time
12:15 PM - 01:25 PM

NOVEL CSF BIOMARKERS FOR SYNAPTIC AND LYSOSOMAL FUNCTION IN NEURODEGENERATIVE DISEASES

Session Type
SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
08:30 AM - 10:30 AM
Room
ONSITE PLENARY: 115-117
Lecture Time
08:30 AM - 08:45 AM

Abstract

Abstract Body

INTRODUCTION: Synaptic and lysosomal dysfunction are hallmark pathological changes in most neurodegenerative diseases. Thus, identification and validation of biomarkers reflecting synaptic and lysosomal dysfunction to be employed as diagnostic and prognostic biomarkers are greatly needed.

METHOD: Solid-phase extraction and parallel reaction monitoring mass spectrometry methods were used to quantify 17 synaptic proteins and 18 lysosomal proteins in CSF, in cross-sectional studies including Alzheimer's disease (AD) patients, patients with different forms of frontotemporal dementia (FTD), Parkinson's disease (PD) and cognitively normal controls.

RESULTS: Increased concentrations of beta-synuclein, gamma-synuclein, neurogranin, PEBP-1, and 14-3-3 proteins were observed in AD patients compared with controls, while neuronal pentraxin-2 and neuronal pentraxin receptor were decreased. In FTD, multiple markers were abnormal in symptomatic MAPT mutations (beta-synuclein, gamma-synuclein, neurogranin, Rab GDP dissociation factor, 14-3-3 eta, syntaxin 1B, syntaxin 7, PBP1 plus NPTX1 and 2), whilst only neuronal pentraxins were affected in symptomatic C9orf72 and GRN mutation carriers. PD patients showed generally low levels of synaptic and lysosomal proteins in their CSF.

DISCUSSION: We have established methods to quantify synaptic and lysosomal proteins in CSF. The results suggest distinct biomarker patterns across neurodegenerative dementias, which correlate with clinical onset and disease progression. Future studies are now needed to examine how the biomarkers change with time and how they respond to treatment with disease-modifying drug candidates.

Hide